This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deziel, M. R.
Right arrow Articles by Drusano, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deziel, M. R.
Right arrow Articles by Drusano, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2005, p. 5099-5106, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.5099-5106.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effective Antimicrobial Regimens for Use in Humans for Therapy of Bacillus anthracis Infections and Postexposure Prophylaxis{dagger}

Mark R. Deziel,1,{ddagger} Henry Heine,2 Arnold Louie,1 Mark Kao,3 William R. Byrne,2 Jennifer Basset,2 Lynda Miller,2 Karen Bush,3 Michael Kelly,3 and G. L. Drusano1*

Ordway Research Institute, Albany, New York,1 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland,2 Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey3

Received 17 April 2005/ Returned for modification 4 June 2005/ Accepted 14 September 2005

Expanded options for treatments directed against pathogens that can be used for bioterrorism are urgently needed. Treatment regimens directed against such pathogens can be identified only by using data derived from in vitro and animal studies. It is crucial that these studies reliably predict the efficacy of proposed treatments in humans. The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for Bacillus anthracis infections and postexposure prophylaxis. An in vitro hollow-fiber infection model that replicates the pharmacokinetic profile of levofloxacin observed in humans (half-life [t1/2], 7.5 h) or in animals, such as the mouse or the rhesus monkey (t1/2, ~2 h), was used to evaluate a proposed indication for levofloxacin (500 mg once daily) for the treatment of Bacillus anthracis infections. The results obtained with the in vitro model served as the basis for the doses and the dose schedules that were evaluated in the mouse inhalational anthrax model. The effects of levofloxacin and ciprofloxacin treatment were compared to those of no treatment (untreated controls). The main outcome measure in the in vitro hollow-fiber infection model was a persistent reduction of culture density (≥4 log10 reduction) and prevention of the emergence of levofloxacin-resistant organisms. In the mouse inhalational anthrax model the main outcome measure was survival. The results indicated that levofloxacin given once daily with simulated human pharmacokinetics effectively sterilized Bacillus anthracis cultures. By using a simulated animal pharmacokinetic profile, a once-daily dosing regimen that provided a human-equivalent exposure failed to sterilize the cultures. Dosing regimens that "partially humanized" levofloxacin exposures within the constraints of animal pharmacokinetics reproduced the antimicrobial efficacy seen with human pharmacokinetics. In a mouse inhalational anthrax model, once-daily dosing was significantly inferior (survival end point) to regimens of dosing every 12 h or every 6 h with identical total daily levofloxacin doses. These results demonstrate the predictive value of the in vitro hollow-fiber infection model with respect to the success or the failure of treatment regimens in animals. Furthermore, the model permits the evaluation of treatment regimens that "humanize" antibiotic exposures in animal models, enhancing the confidence with which animal models may be used to reliably predict the efficacies of proposed antibiotic treatments in humans in situations (e.g., the release of pathogens as agents of bioterrorism or emerging infectious diseases) where human trials cannot be performed. A treatment regimen effective in rhesus monkeys was identified.

* Corresponding author. Mailing address: Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208. Phone: (518) 641-6410. Fax: (518) 641-6304. E-mail: gdrusano{at}ordwayresearch.org.

{dagger} This paper is dedicated to the memory of Mark R. Deziel.

{ddagger} Deceased.

Antimicrobial Agents and Chemotherapy, December 2005, p. 5099-5106, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.5099-5106.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Drusano, G. L., Okusanya, O. O., Okusanya, A. O., van Scoy, B., Brown, D. L., Fregeau, C., Kulawy, R., Kinzig, M., Sorgel, F., Heine, H. S., Louie, A. (2009). Impact of Spore Biology on the Rate of Kill and Suppression of Resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 53: 4718-4725 [Abstract] [Full Text]  
  • Gumbo, T., Siyambalapitiyage Dona, C. S. W., Meek, C., Leff, R. (2009). Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs. Antimicrob. Agents Chemother. 53: 3197-3204 [Abstract] [Full Text]  
  • Lee, J. J., Johnson, S. J., Sohmer, M. J. (2009). Guide for mass prophylaxis of hospital employees in preparation for a bioterrorist attack. Am J Health Syst Pharm 66: 570-575 [Abstract] [Full Text]  
  • Chand, H. S., Drysdale, M., Lovchik, J., Koehler, T. M., Lipscomb, M. F., Lyons, C. R. (2009). Discriminating Virulence Mechanisms among Bacillus anthracis Strains by Using a Murine Subcutaneous Infection Model. Infect. Immun. 77: 429-435 [Abstract] [Full Text]  
  • Drusano, G. L., Okusanya, O. O., Okusanya, A., Van Scoy, B., Brown, D. L., Kulawy, R., Sorgel, F., Heine, H. S., Louie, A. (2008). Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis?. Antimicrob. Agents Chemother. 52: 3973-3979 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Bassett, A., Ivins, B. E., Lehoux, D., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2008). Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax. Antimicrob. Agents Chemother. 52: 3350-3357 [Abstract] [Full Text]  
  • Louie, A., Heine, H. S., Kim, K., Brown, D. L., VanScoy, B., Liu, W., Kinzig-Schippers, M., Sorgel, F., Drusano, G. L. (2008). Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52: 2486-2496 [Abstract] [Full Text]  
  • Ambrose, P. G., Forrest, A., Craig, W. A., Rubino, C. M., Bhavnani, S. M., Drusano, G. L., Heine, H. S. (2007). Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model. Antimicrob. Agents Chemother. 51: 4351-4355 [Abstract] [Full Text]  
  • Louie, A., Deziel, M. R., Liu, W., Drusano, G. L. (2007). Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague Therapy. Antimicrob. Agents Chemother. 51: 2661-2667 [Abstract] [Full Text]  
  • Kedar, G. C., Brown-Driver, V., Reyes, D. R., Hilgers, M. T., Stidham, M. A., Shaw, K. J., Finn, J., Haselbeck, R. J. (2007). Evaluation of the metS and murB Loci for Antibiotic Discovery Using Targeted Antisense RNA Expression Analysis in Bacillus anthracis. Antimicrob. Agents Chemother. 51: 1708-1718 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Hartings, J. M., Ivins, B. E., Pitt, M. L., Fritz, D., Norris, S. L., Byrne, W. R. (2007). Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model. Antimicrob. Agents Chemother. 51: 1373-1379 [Abstract] [Full Text]  
  • Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., Louie, A. (2007). Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. Antimicrob. Agents Chemother. 51: 968-974 [Abstract] [Full Text]  
  • Kao, L. M., Bush, K., Barnewall, R., Estep, J., Thalacker, F. W., Olson, P. H., Drusano, G. L., Minton, N., Chien, S., Hemeryck, A., Kelley, M. F. (2006). Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model. Antimicrob. Agents Chemother. 50: 3535-3542 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»